Obesity Medicine

The investigational dual GLP-1/GLP-2 agonist led to 11.6% weight loss over 28 weeks with no lifestyle changes, showing strong safety and tolerability in the trial.

The American College of Lifestyle Medicine recently published "that guideline," and lead author Richard Rosenfeld, MD, MPH, MBA, says the timing was right.

Both oral and subcutaneous formulations of the long-acting GLP-1 and amylin receptor agonist move into stage 3 clinical trials following positive feedback from regulators.

Your daily dose of the clinical news you may have missed.

High discontinuation rates as well as lower maintenance dosages of semaglutide and tirzepatide were among the independent predictors of lower real-world weight loss.

Novel guidelines include specific strategies that support the prescription, implementation, and monitoring of lifestyle changes to reach glycemic control and, possibly, disease remission.

Donna Ryan, MD, highlights how the media has helped to reframe obesity as a chronic disease and how antiobesity drugs are transforming metabolic disease treatment.

When asked about her 3 wishes for the future of obesity care, Donna Ryan, MD, told Patient Care that she had just one: access.

Your daily dose of the clinical news you may have missed.

Interim results from COURAGE trial suggest combining semaglutide with muscle-preserving antibodies significantly enhances fat loss while preserving lean mass in obesity treatment.

Enobosarm added to semaglutide shows promising results in preserving muscle mass while promoting fat loss in older adults, according to developer Veru, Inc.

GLP-1 receptor agonists showed promise in lowering obesity-related cancer risks in adults with type 2 diabetes, particularly colorectal cancer.

Johanna Finkle, MD, outlines how clinicians can adapt weight management counseling during key stages of a woman’s life, from preconception through menopause.

ACOG 2025: Johanna Finkle, MD, shares strategies to start weight conversations with patients and build clinician confidence in counseling and treatment options.

Semaglutide dosing was individually tailored for adults with obesity and supported with app-based coaching on diet, physical activity, and other lifestyle factors.

Full results from the SURMOUNT-5 trial showed tirzepatide achieved 20.2% mean weight loss vs 13.7% with semaglutide in adults with obesity or overweight.

The ability to predict which individuals will experience adverse events from GLP-1 therapy has great promise for more personalized treatment and improved clinical trial design.

Your daily dose of the clinical news you may have missed.

Phenomix will showcase new data on prediction of adverse events to GLP-1 RA therapy, a new obesity sub-phenotype, and approaches to improve surgical outcomes.

Northstrive Biosciences received positive FDA feedback for its IND application for EL-22, a probiotic-based treatment for obesity.

While smoking in the US continues to decline, the American Cancer Society reports mixed progress in major cancer risk factors, prevention, and screening.

The positive topline data from the phase 3 ACHIEVE-1 trial suggest the small molecule GLP-1 mimetic could compete with blockbuster weekly injectables for reducing weight, A1c.

ACP 2025: GLP-1 medications are advancing obesity care, but lifestyle changes and bariatric surgery remain key components. Laura Davisson, MD, discusses how to personalize treatment strategies.

Following a Mediterranean-style diet and a prescribed regimen of physical activity was significantly protective of BMD, particularly at the lumbar level, over 3 years.

The FDA and Novo Nordisk are urging health care professionals to check semaglutide (Ozempic) injection 1 mg lot PAR0362 with serials starting 51746517.